Scholarlink

Background <p>Astragaloside IV (AS-IV), a key monomeric compound extracted from the traditional Chinese medicine <i>Astragalus membranaceus</i>, has demonstrated significant therapeutic potential in cancer treatment. Hepatocellular carcinoma (HCC), as a malignant tumor posing severe threats to global health, is characterized by high incidence and mortality rates, imposing substantial burdens on patients, families, and society. Numerous studies have demonstrated that AS-IV exhibits significant inhibitory effects on HCC. However, the precise underlying mechanisms remain unclear. Therefore, this systematic review provides a comprehensive summary of current research findings.</p> Methods <p>This systematic review comprehensively evaluates the molecular mechanisms of AS-IV in HCC through extensive literature retrieval from five authoritative databases, encompassing studies published from their inception to March 2025.</p> Results <p>A total of 172 potentially relevant articles were retrieved through database search. After screening, a total of 16 articles finally met the qualification criteria.</p> Conclusion <p>Current evidence indicates that AS-IV exerts crucial therapeutic effects in HCC through multiple pathways: inhibiting tumor cell proliferation, migration, and invasion; inducing apoptosis; modulating immune responses; reducing drug resistance while enhancing chemosensitivity; and suppressing angiogenesis. However, large-scale, well-designed multicenter randomized controlled trials are warranted to establish more robust clinical evidence, thereby solidifying the foundation for AS-IV's broader application in HCC therapeutics.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Molecular mechanisms of astragaloside-IV in hepatocellular carcinoma therapy: a systematic review

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月1日

查看全文
  • Xin Gao,
  • Wen Hao,
  • Yike Wang,
  • Xiaqiu Wu,
  • Feiye Zhu,
  • Yongsheng Zhang

摘要

Background

Astragaloside IV (AS-IV), a key monomeric compound extracted from the traditional Chinese medicine Astragalus membranaceus, has demonstrated significant therapeutic potential in cancer treatment. Hepatocellular carcinoma (HCC), as a malignant tumor posing severe threats to global health, is characterized by high incidence and mortality rates, imposing substantial burdens on patients, families, and society. Numerous studies have demonstrated that AS-IV exhibits significant inhibitory effects on HCC. However, the precise underlying mechanisms remain unclear. Therefore, this systematic review provides a comprehensive summary of current research findings.

Methods

This systematic review comprehensively evaluates the molecular mechanisms of AS-IV in HCC through extensive literature retrieval from five authoritative databases, encompassing studies published from their inception to March 2025.

Results

A total of 172 potentially relevant articles were retrieved through database search. After screening, a total of 16 articles finally met the qualification criteria.

Conclusion

Current evidence indicates that AS-IV exerts crucial therapeutic effects in HCC through multiple pathways: inhibiting tumor cell proliferation, migration, and invasion; inducing apoptosis; modulating immune responses; reducing drug resistance while enhancing chemosensitivity; and suppressing angiogenesis. However, large-scale, well-designed multicenter randomized controlled trials are warranted to establish more robust clinical evidence, thereby solidifying the foundation for AS-IV's broader application in HCC therapeutics.